271 related articles for article (PubMed ID: 23026567)
1. Group IIa secretory phospholipase expression correlates with group IIa secretory phospholipase inhibition-mediated cell death in K-ras mutant lung cancer cells.
Yu JA; Li H; Meng X; Fullerton DA; Nemenoff RA; Mitchell JD; Weyant MJ
J Thorac Cardiovasc Surg; 2012 Dec; 144(6):1479-85. PubMed ID: 23026567
[TBL] [Abstract][Full Text] [Related]
2. Knockdown of secretory phospholipase A2 IIa reduces lung cancer growth in vitro and in vivo.
Yu JA; Mauchley D; Li H; Meng X; Nemenoff RA; Fullerton DA; Weyant MJ
J Thorac Cardiovasc Surg; 2012 Nov; 144(5):1185-91. PubMed ID: 23079010
[TBL] [Abstract][Full Text] [Related]
3. Lung cancer cell invasion and expression of intercellular adhesion molecule-1 (ICAM-1) are attenuated by secretory phospholipase A₂ inhibition.
Yu JA; Sadaria MR; Meng X; Mitra S; Ao L; Fullerton DA; Weyant MJ
J Thorac Cardiovasc Surg; 2012 Feb; 143(2):405-11. PubMed ID: 22248682
[TBL] [Abstract][Full Text] [Related]
4. Group IIa sPLA2 inhibition attenuates NF-κB activity and promotes apoptosis of lung cancer cells.
Yu JA; Kalatardi S; Dohse J; Sadaria MR; Meng X; Fullerton DA; Weyant MJ
Anticancer Res; 2012 Sep; 32(9):3601-7. PubMed ID: 22993297
[TBL] [Abstract][Full Text] [Related]
5. Low frequency of p53 and k-ras codon 12 mutations in non-small cell lung carcinoma (NSCLC) tumors and surgical margins.
Vatan O; Bilaloglu R; Tunca B; Cecener G; Gebitekin C; Egeli U; Yakut T; Urer N
Tumori; 2007; 93(5):473-7. PubMed ID: 18038880
[TBL] [Abstract][Full Text] [Related]
6. IL6 Blockade Reprograms the Lung Tumor Microenvironment to Limit the Development and Progression of K-ras-Mutant Lung Cancer.
Caetano MS; Zhang H; Cumpian AM; Gong L; Unver N; Ostrin EJ; Daliri S; Chang SH; Ochoa CE; Hanash S; Behrens C; Wistuba II; Sternberg C; Kadara H; Ferreira CG; Watowich SS; Moghaddam SJ
Cancer Res; 2016 Jun; 76(11):3189-99. PubMed ID: 27197187
[TBL] [Abstract][Full Text] [Related]
7. Mutations of p53 and KRAS activate NF-κB to promote chemoresistance and tumorigenesis via dysregulation of cell cycle and suppression of apoptosis in lung cancer cells.
Yang L; Zhou Y; Li Y; Zhou J; Wu Y; Cui Y; Yang G; Hong Y
Cancer Lett; 2015 Feb; 357(2):520-6. PubMed ID: 25499080
[TBL] [Abstract][Full Text] [Related]
8. Anthrax lethal toxin down-regulates type-IIA secreted phospholipase A(2) expression through MAPK/NF-kappaB inactivation.
Raymond B; Ravaux L; Mémet S; Wu Y; Sturny-Leclère A; Leduc D; Denoyelle C; Goossens PL; Payá M; Raymondjean M; Touqui L
Biochem Pharmacol; 2010 Apr; 79(8):1149-55. PubMed ID: 19962969
[TBL] [Abstract][Full Text] [Related]
9. Molecular mechanisms underlying the synergistic interaction of erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor, with the multitargeted antifolate pemetrexed in non-small-cell lung cancer cells.
Giovannetti E; Lemos C; Tekle C; Smid K; Nannizzi S; Rodriguez JA; Ricciardi S; Danesi R; Giaccone G; Peters GJ
Mol Pharmacol; 2008 Apr; 73(4):1290-300. PubMed ID: 18187583
[TBL] [Abstract][Full Text] [Related]
10. Oncogenic KRAS-induced epiregulin overexpression contributes to aggressive phenotype and is a promising therapeutic target in non-small-cell lung cancer.
Sunaga N; Kaira K; Imai H; Shimizu K; Nakano T; Shames DS; Girard L; Soh J; Sato M; Iwasaki Y; Ishizuka T; Gazdar AF; Minna JD; Mori M
Oncogene; 2013 Aug; 32(34):4034-42. PubMed ID: 22964644
[TBL] [Abstract][Full Text] [Related]
11. MET gene copy number in non-small cell lung cancer: molecular analysis in a targeted tyrosine kinase inhibitor naïve cohort.
Beau-Faller M; Ruppert AM; Voegeli AC; Neuville A; Meyer N; Guerin E; Legrain M; Mennecier B; Wihlm JM; Massard G; Quoix E; Oudet P; Gaub MP
J Thorac Oncol; 2008 Apr; 3(4):331-9. PubMed ID: 18379349
[TBL] [Abstract][Full Text] [Related]
12. A bifunctional role for group IIA secreted phospholipase A2 in human rheumatoid fibroblast-like synoviocyte arachidonic acid metabolism.
Bryant KJ; Bidgood MJ; Lei PW; Taberner M; Salom C; Kumar V; Lee L; Church WB; Courtenay B; Smart BP; Gelb MH; Cahill MA; Graham GG; McNeil HP; Scott KF
J Biol Chem; 2011 Jan; 286(4):2492-503. PubMed ID: 21068383
[TBL] [Abstract][Full Text] [Related]
13. Secreted phospholipase A2-IIA modulates key regulators of proliferation on astrocytoma cells.
Martín R; Hernández M; Ibeas E; Fuentes L; Salicio V; Arnés M; Nieto ML
J Neurochem; 2009 Nov; 111(4):988-99. PubMed ID: 19737348
[TBL] [Abstract][Full Text] [Related]
14. Lovastatin overcomes gefitinib resistance in human non-small cell lung cancer cells with K-Ras mutations.
Park IH; Kim JY; Jung JI; Han JY
Invest New Drugs; 2010 Dec; 28(6):791-9. PubMed ID: 19760159
[TBL] [Abstract][Full Text] [Related]
15. A gene expression signature of RAS pathway dependence predicts response to PI3K and RAS pathway inhibitors and expands the population of RAS pathway activated tumors.
Loboda A; Nebozhyn M; Klinghoffer R; Frazier J; Chastain M; Arthur W; Roberts B; Zhang T; Chenard M; Haines B; Andersen J; Nagashima K; Paweletz C; Lynch B; Feldman I; Dai H; Huang P; Watters J
BMC Med Genomics; 2010 Jun; 3():26. PubMed ID: 20591134
[TBL] [Abstract][Full Text] [Related]
16. Expression of TLR9 in tumor-infiltrating mononuclear cells enhances angiogenesis and is associated with a worse survival in lung cancer.
Belmont L; Rabbe N; Antoine M; Cathelin D; Guignabert C; Kurie J; Cadranel J; Wislez M
Int J Cancer; 2014 Feb; 134(4):765-77. PubMed ID: 23913633
[TBL] [Abstract][Full Text] [Related]
17. Comparison of EGFR and K-RAS gene status between primary tumours and corresponding metastases in NSCLC.
Kalikaki A; Koutsopoulos A; Trypaki M; Souglakos J; Stathopoulos E; Georgoulias V; Mavroudis D; Voutsina A
Br J Cancer; 2008 Sep; 99(6):923-9. PubMed ID: 19238633
[TBL] [Abstract][Full Text] [Related]
18. Differential expression of secretory phospholipases A2 in normal and malignant prostate cell lines: regulation by cytokines, cell signaling pathways, and epigenetic mechanisms.
Menschikowski M; Hagelgans A; Gussakovsky E; Kostka H; Paley EL; Siegert G
Neoplasia; 2008 Mar; 10(3):279-86. PubMed ID: 18320072
[TBL] [Abstract][Full Text] [Related]
19. Group IIA secretory phospholipase A(2) stimulates inducible nitric oxide synthase expression via ERK and NF-kappaB in macrophages.
Baek SH; Lim JH; Park DW; Kim SY; Lee YH; Kim JR; Kim JH
Eur J Immunol; 2001 Sep; 31(9):2709-17. PubMed ID: 11536169
[TBL] [Abstract][Full Text] [Related]
20. EGFR promotes lung tumorigenesis by activating miR-7 through a Ras/ERK/Myc pathway that targets the Ets2 transcriptional repressor ERF.
Chou YT; Lin HH; Lien YC; Wang YH; Hong CF; Kao YR; Lin SC; Chang YC; Lin SY; Chen SJ; Chen HC; Yeh SD; Wu CW
Cancer Res; 2010 Nov; 70(21):8822-31. PubMed ID: 20978205
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
